Q3 2025 Getinge AB Earnings Call Transcript
Key Points
- Getinge AB (GNGBY) achieved a 9.5% organic growth in net sales, with positive development across all business areas and regions.
- The company improved its adjusted gross and EBITDA margins due to acquisitions, healthy price increases, positive product mix, and productivity gains.
- Recurring revenue products now account for 65% of sales, and high-margin products make up more than two-thirds of sales.
- The financial position remains solid with a financial leverage well below 2.5 times EBITDA.
- Getinge AB (GNGBY) has successfully implemented productivity improvements, such as reducing lead times by more than 20% and cutting costs of goods sold by about 10% for key products.
- The company faces significant headwinds from tariffs and currency fluctuations, impacting EBITDA margins.
- Tariffs have cost the company approximately SEK108 million in Q3, with a year-to-date impact of minus SEK218 million.
- The surgical workflows segment experienced a decline in organic order intake despite strong trends in operating tables and infection control consumables.
- There is uncertainty regarding the timing of new product filings, such as the Cardiosave and cordio solutions in Europe.
- The company is dealing with geopolitical uncertainties and NIH budget constraints, which may impact future sales growth.
Welcome to the Getinge Q3 report 2025 presentation. (Operator Instructions)
Now I will hand the conference over to the speakers, CEO, Mattias Perjos; and CFO, Agneta Palmer. Please go ahead.
Thank you very much, and welcome everyone to today's conference. Today we will first look into our performance in the third quarter and then also reflect a bit on the current market situation and our expectations for the remainder of 2025. So we can move over to page number 2, please.
So if we start by looking at the development of some of our long-term or strategic KPIs, we can see that we continue to clearly track in line with our plan to increase the share of sales from recurring revenue products and also accelerating the share of sales from high margin products like our Paragonix offering, our ECLS portfolio, the consumables in Infection Control and our BetaBags in Sterile Transfer.
This is all supported by solid and effective quality processes as well. Sales from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
